Getting drugs into the brain is one of the hardest problems in all of medicine. The blood-brain barrier blocks almost everything.
But there is a back door. The nose connects directly to the brain through the olfactory nerve. This pathway is changing how scientists think about treating brain diseases with peptide drugs.
- The blood-brain barrier blocks over 98 percent of drugs, but the nose-to-brain pathway bypasses it entirely via olfactory and trigeminal nerves.
- Intranasal delivery enables peptide drugs to reach the brain directly without systemic side effects or invasive procedures.
- Olfactory and trigeminal nerve pathways each target different brain regions, offering flexibility for treating various neurological conditions.
- Specialized formulations using mucoadhesive polymers, nanoparticles, or absorption enhancers are critical for maximizing brain-targeted nasal drug delivery.
- Intranasal insulin for Alzheimer disease is the most advanced nose-to-brain peptide candidate, with clinical trial data supporting safety and efficacy.
- Hiring scientists experienced in nasal formulation, CNS pharmacology, and device engineering is essential for advancing nose-to-brain peptide programs.
The Blood-Brain Barrier: Why It Is So Hard to Cross
The blood-brain barrier (BBB) is a protective layer of tightly connected cells that lines the blood vessels in the brain. It blocks most molecules from passing from the blood into brain tissue.
The BBB evolved to protect the brain from toxins and pathogens. It does a good job. But it also blocks most drugs, including nearly all large molecules like peptides and proteins.
Only very small, fat-soluble molecules cross the BBB easily. Most peptides are water-soluble and medium to large in size. This means that even if a peptide drug reaches the bloodstream at a high concentration, almost none of it gets into the brain.
"The blood-brain barrier is responsible for the failure of over 98% of small molecule CNS drugs and essentially all large molecule drugs in clinical trials. The nasal route offers a fundamentally different approach that sidesteps this problem." - Dr. William Frey, HealthPartners Institute
The Nose-to-Brain Pathway
The nasal cavity is not just a breathing passage. It contains specialized nerve fibers that connect directly to the brain. These nerves bypass the BBB entirely.
There are two main pathways drugs can take from the nose to the brain:
The Olfactory Pathway
The olfactory nerve is the first cranial nerve. It starts in the top of the nasal cavity, where specialized olfactory neurons detect smells. These neurons send their fibers through tiny holes in the skull bone (the cribriform plate) directly into the olfactory bulb of the brain.
Drug molecules that deposit on the olfactory epithelium can travel along these nerve fibers into the brain. This is called axonal transport. It is slow (about 1-2 mm per hour) but bypasses the BBB.
The Trigeminal Pathway
The trigeminal nerve covers most of the nasal cavity. It also extends into the brainstem. Drugs absorbed through the nasal mucosa can enter the trigeminal nerve and travel into deeper brain regions.
The trigeminal pathway is generally faster than the olfactory pathway and reaches different brain areas.
| Pathway | Starting Point | Brain Region Reached | Speed |
|---|---|---|---|
| Olfactory nerve | Olfactory epithelium (top of nasal cavity) | Olfactory bulb, frontal cortex, hippocampus | Slow (hours) |
| Trigeminal nerve | Respiratory epithelium | Brainstem, cerebellum, deep brain | Faster (minutes to hours) |
| Vascular (indirect) | Nasal blood vessels | Whole brain (BBB still applies) | Fast (minutes) |
| Lymphatic | Nasal lymphatics | Cervical lymph nodes, then brain indirectly | Slow |
The olfactory nerve is the only cranial nerve directly exposed to the external environment, making the nasal cavity a unique drug delivery portal that connects to the brain within minutes.
Why Intranasal Delivery Is So Attractive for CNS Peptides
Beyond bypassing the BBB, the intranasal route has several practical benefits:
- Non-invasive: Much easier than intrathecal (spinal) or intracerebroventricular injections
- Rapid onset: Some drugs reach the brain within 30 minutes of nasal application
- Patient-friendly: Nasal sprays are familiar and easy to self-administer
- Avoids first-pass metabolism: Drug goes directly to the brain, not through the liver first
- Lower systemic exposure: Less drug in the blood means fewer systemic side effects
Desmopressin, a synthetic peptide analog of vasopressin, has been delivered intranasally for decades to treat diabetes insipidus and bedwetting. Its nasal form (DDAVP nasal spray) is a real-world example of a peptide drug delivered via the nose.
Peptides Being Studied for Nose-to-Brain Delivery
Several important peptides are under active investigation for intranasal delivery to the brain:
Insulin: Intranasal insulin is being studied for Alzheimer's disease. The brain has insulin receptors, and insulin signaling is disrupted in Alzheimer's. Multiple clinical trials have shown that intranasal insulin improves memory scores in early Alzheimer's patients without significantly affecting blood glucose.
Oxytocin: The "bonding hormone" is being tested intranasally for autism spectrum disorder, social anxiety, and PTSD. Brain imaging studies show that intranasal oxytocin reaches the amygdala and affects social behavior.
Neuropeptide Y: Being studied for anxiety, epilepsy, and brain injury. Its ability to reduce seizure activity makes it a target for intranasal delivery.
BDNF (Brain-Derived Neurotrophic Factor): A protein that promotes neuron survival. Being explored for Parkinson's disease and depression.
NAP (NAPVSIPQ) peptide: An eight-amino-acid peptide derived from a brain protein (ADNP). Shows neuroprotective effects in Alzheimer's models after intranasal administration.
Nasal Anatomy and Formulation Considerations
The nose is not a simple tube. Its anatomy greatly affects where a drug deposits and which pathway it takes.
| Nasal Region | Surface Area | Drug Fate |
|---|---|---|
| Nasal vestibule | Small | Low absorption, mostly swallowed |
| Respiratory epithelium | Large (~150 cm2) | Systemic absorption via blood vessels |
| Olfactory epithelium | Small (~5 cm2) | Direct nose-to-brain transport |
| Nasopharynx | Small | Drug swallowed into GI tract |
The olfactory region is only a small fraction of the total nasal surface area. To maximize nose-to-brain delivery, the drug needs to deposit in this specific area at the top of the nasal cavity. Most standard nasal sprays deposit mainly in the anterior nasal cavity, far from the olfactory region.
This targeting problem has driven development of new nasal delivery devices designed to direct drug toward the olfactory epithelium.
When building a nose-to-brain peptide program, prioritize hiring formulation scientists with hands-on experience in mucoadhesive polymer systems and nasal device engineering, because even a promising peptide candidate will fail without a delivery vehicle optimized for nasal residence time and olfactory uptake.
Delivery Devices for Intranasal Peptide Brain Delivery
Standard pump spray bottles are not ideal for nose-to-brain delivery. Better options include:
Bidirectional devices (like the Optinose system): The patient exhales through the nose while the device releases drug. This uses the patient's own airflow to carry drug particles to the upper nasal cavity near the olfactory region.
Nasal powder delivery systems: Dry powder formulations can reach the olfactory region more effectively than liquid sprays. Devices like the Aptar Monopowder system are designed for this.
Nasally targeted liquid sprays: Special nozzle designs and patient head positioning (head tilted back and to the side) can improve deposition in the olfactory area.
"The device is as important as the formulation for nose-to-brain delivery. If the drug does not reach the olfactory epithelium, the pathway is not engaged. Device development and formulation development must happen together." - Dr. Pran Bhatt, Intranasal Therapeutics
Formulation Strategies for Intranasal Peptide Drugs
The formulation must keep the peptide stable in the nasal environment and help it reach and cross the nasal epithelium. For authoritative context, see the NIH research on intranasal drug delivery.
Key considerations include:
Mucosal clearance: The nose clears mucus every 15-30 minutes. A drug applied as a simple solution will be cleared before much absorption occurs. Mucoadhesive formulations that stick to the nasal lining extend contact time.
Common mucoadhesive polymers used in nasal formulations:
- Chitosan
- Hyaluronic acid
- Carbopol (carbomer)
- Hydroxypropyl methylcellulose (HPMC)
Absorption enhancers: Similar to oral delivery, permeation enhancers can help peptides cross the nasal epithelium into the underlying tissue and nerve fibers.
Common intranasal enhancers:
- Cyclodextrins: Solubilize peptides and enhance membrane permeation
- Chitosan: Mucoadhesion plus tight junction opening
- Surfactants: Used at low concentrations to disrupt mucus barriers
- Cell-penetrating peptides: Short peptides that help other peptides cross membranes
pH and tonicity: The nasal mucosa functions best at near-neutral pH (6.8-7.2). Solutions that are too acidic or too alkaline can irritate the nose and reduce absorption. Isotonic formulations (close to body salt concentration) are better tolerated.
Nanoparticle formulations for nasal delivery: Chitosan nanoparticles, lipid nanoparticles, and polymeric nanoparticles loaded with peptides have shown improved nose-to-brain delivery in animal studies. The particles protect the peptide and interact with the olfactory nerve more efficiently than free peptide.
Animal and Clinical Evidence
Most nose-to-brain peptide delivery evidence comes from animal studies. Rats and mice are common models. However, the olfactory epithelium in rodents covers a much larger fraction of the nasal cavity than in humans. This makes translation to humans tricky.
In humans, the most clinically advanced example is intranasal insulin for Alzheimer's disease. Studies by Dr. Suzanne Craft and colleagues at Wake Forest University showed significant improvements in memory and cognitive function in Alzheimer's patients treated with intranasal insulin. A large Phase 3 trial is ongoing.
Other clinical trials are ongoing for intranasal oxytocin, neuropeptide Y, and several neuroprotective peptides.
FAQs About Intranasal Peptide Delivery to the Brain
Does intranasal delivery really get drugs into the brain?
Yes, studies using radiolabeled drugs in animals and some imaging studies in humans confirm that drugs applied to the olfactory region of the nose can reach the brain without entering the bloodstream first. The efficiency is low in absolute terms, but it is higher than crossing the blood-brain barrier through blood.
Is intranasal insulin safe for Alzheimer's patients?
Clinical trials of intranasal insulin in Alzheimer's patients have shown a good safety profile. Because only a small fraction of the nasally applied insulin reaches the bloodstream, blood glucose is not significantly affected in most patients. The nasal insulin doses used are much lower than therapeutic insulin injection doses.
What diseases could benefit most from nose-to-brain peptide delivery?
Diseases where the brain is the primary target are the best candidates. These include Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, depression, anxiety, autism spectrum disorder, and traumatic brain injury. Any condition where a therapeutic peptide exists but cannot cross the BBB is a potential target.
How much of a nasal dose actually reaches the brain?
The efficiency is low. Studies suggest that 0.1% to 1% of a nasal dose reaches the brain via the olfactory pathway in humans. This sounds small, but for very potent peptides (like neuropeptides that act at nanogram doses), this may be enough. Formulation optimization and better devices are actively improving these numbers.
Can any nasal spray reach the brain, or does it require special formulations?
Standard nasal sprays mostly deposit in the front of the nose and are absorbed into blood vessels or swallowed. Reaching the brain via the olfactory pathway requires targeted deposition at the top of the nasal cavity. This needs either special devices or formulations (like mucoadhesive nanoparticles) to improve olfactory region targeting.
Staff Your Nose-to-Brain Peptide Delivery Program With PeptideStaff
Nose-to-brain peptide delivery is a specialized and rapidly growing field. It needs scientists who understand nasal anatomy, BBB biology, peptide formulation, and CNS pharmacology all at once.
PeptideStaff helps pharmaceutical and biotech companies recruit experienced researchers and development scientists for intranasal CNS peptide programs. We know where these experts are and how to connect you with them.
Contact PeptideStaff today to find intranasal CNS peptide delivery specialists.
Topics
Dr. Lisa Park
Regulatory Affairs Specialist
PharmD | 9 years in peptide pharmaceutical compliance
Focuses on FDA, DEA, and state pharmacy board regulations governing peptide compounds. Guides compounding pharmacies and peptide manufacturers through changing compliance landscapes.
Reviewed by Dr. Lisa Park, PharmD, April 2026